These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26484998)

  • 41. Myocardial infarction and atrial fibrillation: different impact of anti-IIa vs anti-Xa new oral anticoagulants: a meta-analysis of the interventional trials.
    Loffredo L; Perri L; Violi F
    Int J Cardiol; 2015 Jan; 178():8-9. PubMed ID: 25464208
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.
    Marcy TR; Truong T; Rai A
    Consult Pharm; 2015 Nov; 30(11):644-56. PubMed ID: 26629800
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long term anticoagulation or antiplatelet treatment. Inclusion criteria determine results of review.
    Mant J; Fitzmaurice D; Murray E; Lip GY; Hobbs FD
    BMJ; 2001 Jul; 323(7306):233-4; author reply 235-6. PubMed ID: 11496884
    [No Abstract]   [Full Text] [Related]  

  • 44. Oral anticoagulation for atrial fibrillation after ST-elevation myocardial infarction: new evidence to guide clinical practice.
    Kushner FG; Antman EM
    Circulation; 2005 Nov; 112(21):3212-4. PubMed ID: 16301351
    [No Abstract]   [Full Text] [Related]  

  • 45. The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials.
    Krishnamoorthy A; Sherwood MW; Lopes RD; Becker RC
    Am Heart J; 2015 Mar; 169(3):315-22. PubMed ID: 25728720
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Population-based evaluation of the management of antithrombotic therapy for atrial fibrillation.
    Anderson DR; Gardner MJ; Putnam W; Jassal D; Brownell B; Flowerdew G; Nagpal S; Thompson K; Cox JL
    Can J Cardiol; 2005 Mar; 21(3):257-66. PubMed ID: 15776115
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Atrial fibrillation and the 'other drug problem': reducing non-adherence with technology.
    Nerini E; Grip L; Camm AJ; Giugliano RP
    Eur Heart J; 2013 Jul; 34(27):2031-3. PubMed ID: 23704706
    [No Abstract]   [Full Text] [Related]  

  • 48. Oral anticoagulants for stroke prevention in atrial fibrillation. Foreword.
    Rahimtoola SH
    Curr Probl Cardiol; 2014 Sep; 39(9):317. PubMed ID: 25194765
    [No Abstract]   [Full Text] [Related]  

  • 49. Update on dabigatran for stroke prevention in atrial fibrillation.
    Henry DM
    Conn Med; 2011 Sep; 75(8):479-83. PubMed ID: 21980679
    [No Abstract]   [Full Text] [Related]  

  • 50. Real-world data on direct-acting oral anticoagulants.
    Rodríguez-Padial L; Arias MÁ; Martín Rodríguez F
    Med Clin (Barc); 2018 Feb; 150(4):161. PubMed ID: 28923668
    [No Abstract]   [Full Text] [Related]  

  • 51. Warfarin for stroke prevention in atrial fibrillation: time to switch?
    Ahmad Y; Lip GY
    Int J Clin Pract; 2013 Jul; 67(7):603-5. PubMed ID: 23758442
    [No Abstract]   [Full Text] [Related]  

  • 52. Target-specific oral anticoagulants for stroke prevention in patients with atrial fibrillation: real-world considerations.
    Rosenberg DJ; Ansell J
    Hosp Pract (1995); 2012 Aug; 40(3):50-7. PubMed ID: 23086094
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Stroke prevention in atrial fibrillation.
    Piccini JP; Wallace TW; Patel MR; Becker RC
    Cardiovasc Drugs Ther; 2011 Dec; 25(6):561-70. PubMed ID: 21927837
    [No Abstract]   [Full Text] [Related]  

  • 54. The promise of pharmacoepidemiology in helping clinicians assess drug risk.
    Avorn J
    Circulation; 2013 Aug; 128(7):745-8. PubMed ID: 23940388
    [No Abstract]   [Full Text] [Related]  

  • 55. Oral antithrombotic therapy in atrial fibrillation associated with acute or chronic coronary artery disease.
    Cairns JA; McMurtry MS
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S60-70. PubMed ID: 23790600
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
    Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Blending Quality Improvement and Research Methods for Implementation Science, Part I: Design and Data Collection.
    Granger BB; Shah BR
    AACN Adv Crit Care; 2015; 26(3):268-74. PubMed ID: 26200736
    [No Abstract]   [Full Text] [Related]  

  • 58. Guidelines are usually the safer road.
    Gjesdal K
    Cardiology; 2007; 107(4):373. PubMed ID: 17284897
    [No Abstract]   [Full Text] [Related]  

  • 59. New oral anticoagulants: their role in stroke prevention in high-risk patients with atrial fibrillation.
    Ferns SJ; Naccarelli GV
    Med Clin North Am; 2015 Jul; 99(4):759-80. PubMed ID: 26042881
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Personalizing oral anticoagulant treatment in patients with atrial fibrillation.
    Capranzano P; Miccichè E; D'Urso L; Privitera F; Tamburino C
    Expert Rev Cardiovasc Ther; 2013 Aug; 11(8):959-73. PubMed ID: 23957907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.